"Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials" by Philip J. Mease

Article

Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials

Arthritis & Rheumatism (2017)

Philip J. Mease, University of Washington
Gerd R. Burmester, Free University of Berlin
Susan Moriarty
Olivier Benichou, Eli Lilly and Company
Wen Xu
Peter Nash, University of Queensland

Link

Disciplines

Physical Therapy and
Medicine and Health Sciences

Publication Date

October 1, 2017

Citation Information

Philip J. Mease, Gerd R. Burmester, Susan Moriarty, Olivier Benichou, et al.. "Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials" Arthritis & Rheumatism Vol. 69 (2017)
Available at: http://works.bepress.com/philip-mease/32/